Sanofi (NASDAQ:SNY) Issues Quarterly Earnings Results, Beats Estimates By $0.48 EPS

Sanofi (NASDAQ:SNY) announced its quarterly earnings data on Friday. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.56 by $0.48, Zacks reports. The company had revenue of $17.25 billion during the quarter, compared to analysts’ expectations of $14.29 billion. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. Sanofi’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.91 EPS.

Here are the key takeaways from Sanofi’s conference call:

• Q3 performance was strong: sales rose 14.3% to €14.4 billion, business operating income increased 19.7%, and business EPS grew 19.6%, supported by demand, favorable gross-to-net adjustments, product mix, and strict cost control.
• Sanofi upgraded its 2026 outlook to sales growth of 13%–15% and business EPS growth of 15%–17%. Management also expects business operating income and margin to increase annually through 2030, despite upcoming headwinds.
• Dupixent remained the central growth engine, generating €5.7 billion in Q3 with more than 1.5 million patients globally. Sanofi reaffirmed confidence in reaching at least €25 billion in annual sales by 2030 and expanded its Regeneron alliance with four next-generation immunology antibodies, including a potential long-acting follow-on product.
• Sanofi is concentrating resources on immunology, rare diseases, and vaccines while pursuing late-stage and commercial assets through disciplined BD and M&A. The company expects to provide more detail on its disease-area priorities, capital allocation, and Dupixent loss-of-exclusivity planning at a strategic update before year-end.
• R&D productivity remains a concern, with management acknowledging that Sanofi’s pipeline lags peers and discontinuing amlitelimab and itepekimab after benefit-risk reviews. The company also cautioned that 2027 sales will face roughly €1.3 billion of divestment-related reductions, a return to slightly negative pricing trends, and continued Dupixent profit-sharing and reimbursement headwinds.

Sanofi Stock Up 2.8%

Shares of SNY stock traded up $1.21 on Friday, reaching $44.34. 15,100,858 shares of the company were exchanged, compared to its average volume of 3,453,743. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The company has a 50-day moving average of $42.21 and a 200-day moving average of $44.35. The company has a market cap of $107.50 billion, a price-to-earnings ratio of 23.21, a PEG ratio of 1.33 and a beta of 0.33. Sanofi has a one year low of $39.07 and a one year high of $52.68.

Key Headlines Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported third-quarter earnings of $2.04 per share, well above the $1.56 analyst consensus, while revenue of $17.25 billion exceeded estimates of $14.29 billion and rose 16.2% year over year. Sanofi earnings report
• Positive Sentiment: Dupixent remained the growth engine, generating approximately $6.36 billion in quarterly sales. Strong demand for the immunology treatment helped Sanofi raise its 2026 sales and business-earnings outlook. Sanofi Q3 earnings and outlook
• Positive Sentiment: The earnings beat and upgraded guidance are improving investor confidence in Sanofi’s near-term growth trajectory, with the stock reacting favorably despite broader weakness in technology shares. Sanofi profit and guidance update
• Neutral Sentiment: Chief Executive Officer Paul Hudson is considering acquisitions and other deals to replenish Sanofi’s pipeline ahead of Dupixent’s eventual patent expiration. Potential transactions could support future growth, but they also introduce execution and capital-allocation risks. Sanofi CEO discusses future deals
• Negative Sentiment: Despite the strong quarter, reported earnings declined from $2.91 per share in the prior-year period, underscoring the importance of sustained Dupixent growth and successful pipeline investments. Sanofi quarterly results

Analyst Ratings Changes

Several analysts recently issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. Wolfe Research started coverage on shares of Sanofi in a research report on Friday, October 9th. They set a “peer perform” rating on the stock. Berenberg Bank reissued a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, September 17th. Finally, Morgan Stanley set a $49.00 price target on Sanofi in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $49.50.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.